Dosage of oseltamivir in children under 6 months of age in the swine flu pandemic

Similar documents
URGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU

Pandemic influenza Recommendations on the use of antiviral medicines for pregnant women, women who are breastfeeding and children under the age of

Pandemic Influenza Weekly Situation Report. Sir Liam Donaldson Chief Medical Officer 23 July 2009

The H1N1 swine flu vaccination programme

CONFIRMED INFLUENZA ISOLATES IN NORTHERN IRELAND - NICE GUIDANCE ON USE OF ANTIVIRALS NOW APPLIES

NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE Thomas R. Frieden, MD, MPH Commissioner

NOVEL INFLUENZA A (H1N1) Swine Flu

Gateway reference : 13683

Swine Influenza Update #3. Triage, Assessment, and Care of Patients Presenting with Respiratory Symptoms

KNOWING RESPONSES: The Case of Swine Flu. Dr Jacky Chambers Dr Andrew Rouse

State of Tennessee Department Of Health Stockpile Antiviral Distribution

TEMPORARY PROGRAMME OF PERTUSSIS (Whooping Cough) VACCINATION OF PREGNANT WOMEN

Pandemic Influenza Preparedness and Response

NHS PREPAREDNESS FOR A MAJOR INCIDENT

Buprenorphine used in the treatment of opioid dependence: availability and price

NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION

Immunisation against infectious disease Updates Chapter 23a Pandemic influenza A(H1N1)v 2009 (swine flu)

Sets out clearly the DoH s expectations of the NHS and the roles and responsibilities of each part of the system over the coming months.

SWINE FLU: FROM CONTAINMENT TO TREATMENT

Antivirals for Avian Influenza Outbreaks

Guidance on use of antiviral agents for the treatment and prophylaxis of influenza,

Influenza Outbreaks. An Overview for Pharmacists Prescribing Antiviral Medications

Directed Enhanced Service (DES) for H1N1 Vaccination Programme JCVI priority groups

Guideline for Antiviral Drugs

What Antivirals Can Be Used for 2009 H1N1 Influenza?

CALDERDALE PRIMARY CARE TRUST

abcdefghijklmnopqrstu

NHS Circular: PCA(M)(2011)4 abcdefghijklmnopqrstu TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH SEVERE DISTRESS. Summary

Access to clinical trial information and the stockpiling of Tamiflu. Department of Health

A brief history of the UK s low risk drinking guidelines

This letter is to notify you of recent changes to the TAMIFLU product monograph. Please note, additions/changes have been highlighted in yellow.

PROFESSOR DAME SALLY C DAVIES CHIEF MEDICAL OFFICER CHIEF SCIENTIFIC ADVISER

Dear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE

Health and Social Care Workers and Pandemic Influenza

US FDA approves XOFLUZA (Baloxavir Marboxil) new drug to treat influenza on 24 th Oct 2018

pí=^åçêéïûë=eçìëé= oéöéåí=oç~ç= bçáåäìêöü=ben=pad= = = IMMEDIATE MESSAGE TO:

Core Standard 24. Cass Sandmann Emergency Planning Officer. Pat Fields Executive Director for Pandemic Flu Planning

Anti-Influenza Agents Quantity Limit Program Summary

Please see the attached drug alert for onward transmission as below.

Guidance on Bulk Prescribing for Care Home Patients

Seasonal Influenza in Pregnancy and Puerperium Guideline (GL1086)

abcdefghijklmnopqrstu

The Scottish Government Riaghaltas na h-alba

Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products

Case scenarios: Patient Group Directions

1 Criteria for triggering the use (both start-up and stoppage) of neuraminidase inhibitors by clinicians for the treatment of influenza in the UK

HEALTH ALERT SWINE INFLUENZA SITUATION UPDATE UPDATED PATIENT TESTING PRIORITIZATION INTERIM GUIDANCE ON ANTIVIRALS

Oral Dose of TAMIFLU for Treatment (twice daily for 5 days) of Influenza in Pediatric Patients One Year of Age and Older by

HOW EFFECTIVE ARE ANTIVIRAL DRUGS AGAINST INFLUENZA? Dr Puja Myles

Thank you for sending us the assessment report for the above technology appraisal. Our response is provided below.

Review of the response to the H1N1 Flu Pandemic 2009/2010 WLMHT

Tamiflu. Tamiflu (oseltamivir) Description

IMMEDIATE DICLOFENAC NEW CONTRAINDICATIONS AND WARNINGS AFTER A EUROPE-WIDE REVIEW OF CARDIOVASCULAR SAFETY

Memo. To: Pandemic Planning Partners. Subject: Pandemic Countermeasures Planning. Date:

WELSH HEALTH CIRCULAR

Technology appraisal guidance Published: 25 February 2009 nice.org.uk/guidance/ta168

Antiviral Prescribing and NICE Guidelines

The Impact of Pandemic Influenza on Public Health

FREQUENTLY ASKED QUESTIONS SWINE FLU

SCIENTIFIC DISCUSSION

Good Practice Guidance on Covert Administration of Medication

Pediatric Infections caused by the Swine-Origin Influenza A (H1N1) Virus (S-OIV) 5/1/09 Update

Preparation of TAMIFLU for Oral Suspension. Emergency Compounding of an Oral Suspension from TAMIFLU Capsules (Final Concentration 15 mg/ml)

Ensuring an Adequate Stockpile of Antivirals. Paul Brown F. Hoffmann La-Roche Basel, Switzerland

ACCESS TO MEDICINES FOR END-OF-LIFE AND VERY RARE CONDITIONS: TRANSITION FROM IPTR TO PACS

Enhanced Service Specification. Childhood seasonal influenza vaccination programme 2017/18

Swine Flu Update and FAQ

Tuberculin PPD 100,000 units in 1 ml for Heaf Testing continues to be available.

AVIAN FLU BACKGROUND ABOUT THE CAUSE. 2. Is this a form of SARS? No. SARS is caused by a Coronavirus, not an influenza virus.

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 April 2008

Introduction of shingles vaccine for people aged 70

Ralph KY Lee Honorary Secretary HKIOEH

PHE guidance on use of antiviral agents for the treatment and prophylaxis of influenza ( ) Version 5.1, January 2015

INFLUENZA FACTS AND RESOURCES

PRODUCT MONOGRAPH. Pr TAMIFLU. oseltamivir capsule 30 mg, 45 mg and 75 mg oseltamivir (as oseltamivir phosphate)

Pandemic Influenza Preparedness

Pandemic influenza. Human resources guidance for the NHS

Influenza. Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong

IS THE UK WELL PREPARED FOR A REPEAT OF THE 1918 INFLUENZA PANDEMIC?

Questions and Answers Regarding Federal Contracts for State-Purchased Antiviral Drugs (Relenza & Tamiflu ) (07/26/06)

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION a Society that includes Basic Science, the Failing Heart, and Advanced Lung Disease

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE

Amantadine, oseltamivir and zanamivir for the treatment of influenza. Review of NICE technology appraisal guidance 58

The prescribing newsletter for GPs, nurses and pharmacists NHS Northamptonshire Failure to respond to first choice antibiotics

Volume 9; Number 3 March 2015 PRESCRIBING AND DISPENSING PREGABALIN FOR NEUROPATHIC PAIN

Guidelines for clinical management of severe influenza infection. Aeron Hurt

Current Swine Influenza Situation Updated frequently on CDC website 109 cases in US with 1 death 57 confirmed cases aroun

Paediatric Prescribing Pocket Guide September 2014 (Version 1)

TRUST WIDE DOCUMENT DOCUMENT NUMBER: ELHT Version 1

abcdefghijklm abcde abc a eé~äíü=aéé~êíãéåí= cêçã=íüé= `ÜáÉÑ=jÉÇáÅ~ä= lññáåéê= = aê=e~êêó=_ìêåë=jme=co`pedä~ëf= co`mebçf=ccme= Dear Colleague

County of Los Angeles Department of Health Services Public Health

Sep Frequently asked questions concerning Pandemic(Swine) Flu

Diagnosing and managing

Managing Influenza Outbreaks in Retirement Home Settings: It s Not Like Long Term Care

UK Teratology Information Service Regional Drug & Therapeutics Centre Wolfson Unit Newcastle upon Tyne NE2 4HH PARTICIPANT INFORMATION SHEET

Distribution: As Appendix 1 Dr Ruth Hussey, Chief Medical Officer, Welsh Government Date: 10 October Ongoing Ebola outbreak in West Africa

Care homes - Homely remedies

Patient/Carer Guide. Subcutaneous injection for routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors

Re: Handling of gabapentin and pregabalin as Schedule 3 Controlled Drugs in health and justice commissioned services

Human Cases of Influenza A (H1N1) of Swine Origin in the United States and Abroad Updated Key Points April 29, 2008: 9:58AM

Transcription:

Gateway ref: 13032 20 November 2009 CAS ref: CEM/CMO/2009/32 Richmond House 79 Whitehall London SE1A 2NS Dear Colleague Dosage of oseltamivir in children under 6 months of age in the swine flu pandemic As indicated in our letter of 24 September 2009 (Gateway Reference: 12664), we are now in a position to tell you about changes to the dose of oseltamivir in children under 6 months of age during an influenza pandemic outbreak and the steps that need taken to ensure a safe transition to the new dosage. Treatment of Children aged under 6 months of age The manufacturer of Tamiflu (oseltamivir), Roche Products Ltd, has been granted a variation to the Market Authorisation for the treatment of children under 6 months of age. The recommended dose for the treatment of newborn children up to 1 month of age remains as: 2 mg per kg body weight given twice a day for 5 days. The recommended dose for the treatment of children over 1 month and up to 3 months of age is: 2.5 mg per kg body weight given twice a day for 5 days The recommended dose for the treatment of children over 3 months of age and under 6 months of age, is now the same as the recommended dose for those aged 6 months and over and under 1 year of age: 3 mg per kg body weight given twice a day for 5 days The liquid formulation of oseltamivir in the national stockpile is Oseltamivir Oral Solution. This has a strength of 15mg in 1ml and is manufactured by designated licensed hospital pharmacy manufacturing units. It is the product that should be routinely used for the treatment of swine flu in children under 1 year. Set out in the table, included at Annex One, is new dosage guidance based on the 15mg in 1ml Oseltamivir Oral Solution. To make authorisation and issuing easier, PCTs have been asked to quarantine the lower strength 12mg in 1ml Oseltamivir Suspension.

Managing the transition General Practitioners and healthcare professionals authorising the supply of oseltamivir for children aged under 6 months of age, and those making the supply from antiviral collection points will need to ensure extra care is taken as this change of dosage is implemented. The implementation should be overseen and supervised by PCT Chief Pharmacists working closely with PCT Directors of Public Health. The Department of Health is issuing two new authorisation vouchers for the supply of oseltamivir for the treatment of children under 1 year during an influenza pandemic. One for children up to 3 months of age and one for children over 3 months of age and under 1 year of age. The new vouchers reflect the agreement reached with the RCGP and BMA in relation to the safe authorisation and supply of antivirals. The new vouchers are now being distributed to GPs directly and should be received by 14 December 2009. Pre-existing vouchers based on the previous doses should continue used until the new vouchers are received. The new vouchers should start used as soon as they are received with the previous vouchers then being destroyed. We are not expecting any further changes to the dose of oseltamivir in the near future but will keep you updated if there are any changes. Prophylaxis The vouchers allow for the possibility of prophylaxis. This recognises that in certain situations, where individuals with a serious underlying condition have been in close contact with an infectious case, clinical judgement may be used to offer a course of prophylaxis. The doses for prophylaxis are shown in the tables in Annex One. The dose recommendations were based on limited evidence to support the use of oseltamivir for the prevention of influenza for children under the age of one year. Doctors should consider very carefully the benefits and risks of prophylactic antiviral medicine for each child under the age of one, and may wish to take advice from a specialist in the care of young children. We hope this information is helpful. Yours sincerely, Sir Liam Donaldson Chief Medical Officer Dr Keith Ridge Pharmaceutical Officer

ANNEX ONE Dosage chart for newborn up to 1 month. TREATMENT: 2mg/kg given twice a day for 5 days PROPHYLAXIS 2mg/kg given once a day for 10 days Dose calculation based on weight and dose of 2 mg/kg 2.0 2.6 0.3 1 x 20 ml 2.7 3.3 0.4 1 x 20 ml 3.4 4.0 0.5 1 x 20 ml 4.1 4.8 0.6 1 x 20 ml 4.9 5.5 0.7 1 x 20 ml

Dosage chart for children over 1 month and up to 3 months of age TREATMENT: 2.5mg/kg given twice a day for 5 days PROPHYLAXIS 2.5mg/kg given once a day for 10 days Dose calculation based on weight and dose of 2.5 mg/kg 3.0 3.5 0.5 1 x 20 ml 3.6 4.1 0.6 1 x 20 ml 4.2 4.7 0.7 1 x 20 ml 4.8 5.3 0.8 1 x 20 ml 5.4 5.9 0.9 1 x 20 ml 6.0 6.5 1.0 1 x 20 ml 6.6 7.1 1.1 1 x 20 ml 7.2 7.7 1.2 1 x 20 ml

Dosage chart for children over 3 months and under 1 year of age TREATMENT: 3mg/kg given twice a day for 5 days PROPHYLAXIS 3mg/kg given once a day for 10 days Dose calculation based on weight and dose of 3 mg/kg 4.5 4.9 0.9 1 x 20 ml 5.0 5.4 1.0 1 x 20 ml 5.5 5.9 1.1 1 x 20 ml 6.0 6.4 1.2 1 x 20 ml 6.5 6.9 1.3 1 x 20 ml 7.0 7.4 1.4 1 x 20 ml 7.5 7.9 1.5 1 x 20 ml 8.0 8.4 1.6 1 x 20 ml 8.5 8.9 1.7 1 x 20 ml 9.0 9.4 1.8 1 x 20 ml 9.5 9.9 1.9 2 x 20 ml 10.0-10.4 2.0 2 x 20 ml 10.5-10.9 2.1 2 x 20 ml 11.0 11.4 2.2 2 x 20 ml 11.5 11.9 2.3 2 x 20 ml 12.0 12.4 2.4 2 x 20 ml